Pirarubicin in advanced breast cancer: a French cooperative phase II study.
79 patients with advanced breast cancer were given Pirarubicin 20-25 mg/m2 during 3 consecutive days every 3 or 4 weeks. 78 were evaluable for response (41 without previous chemotherapy and 37 with only one previous regimen). The overall response rate was 35% (95% CI 24-45) and the complete response rate was 8%. In previously untreated patients, the response rate reached 41.5%. The limiting toxicity was a non-cumulative granulocystopenia, sometimes severe at these high doses, with a prompt recovery. The non-haematological toxicities were mild, and included 13% with grade 3 alopecia.
Spielmann
M
M
Institut Gustave Roussy, Villejuif, France.
Kerbrat
P
P
Delozier
T
T
Fumoleau
P
P
Monnier
A
A
Chevallier
B
B
Bastit
P
P
Namer
M
M
Cattan
A
A
Lucas
P
P
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D008875:Middle Aged
D000970:Antineoplastic Agents; D004317:Doxorubicin; C027260:pirarubicin